Cambridge Enterprise

Pretzel Therapeutics is a biotechnology company focused on developing therapies for mitochondrial dysfunction. Founded by leading experts in mitochondrial biology, the company aims to create innovative treatments that address the underlying causes of mitochondrial issues. By leveraging a comprehensive understanding of mitochondrial mechanisms, Pretzel Therapeutics seeks to reverse dysfunction at its roots, potentially providing effective solutions for patients suffering from a range of conditions, including those related to aging. The company's name reflects its scientific focus on the mitochondrion, which is characterized by its unique and highly folded inner membrane, distinguishing it from other organelles in the body.

CardiaTec is a digital biotechnology company focused on revolutionizing cardiovascular drug discovery through the integration of artificial intelligence and specialized expertise. The company aims to transform the understanding of cardiovascular disease by developing AI-driven platforms for target identification and novel drug discovery. This approach seeks to provide effective therapeutics for cardiovascular diseases, addressing significant gaps in diagnostics, patient stratification, and treatment options for conditions such as coronary artery disease. By leveraging advanced technology and scientific knowledge, CardiaTec is dedicated to improving healthcare outcomes related to cardiovascular health.

Spirea Ltd. operates as a healthcare technology company that has developed a smart polymer platform for the controlled delivery of drug combinations to maximise the clinical impact of medicines.

Colorifix Limited, founded in 2016 and based in Norwich, United Kingdom, specializes in innovative textile dyeing services using biological methods. The company harnesses color-producing organisms, including microbes, plants, animals, and insects, to create a diverse range of colors. By converting agricultural by-products like sugar molasses into environmentally friendly colorants, Colorifix offers a sustainable alternative to traditional dyeing practices. It is recognized as the first company to implement biological dyeing commercially for polyamide-based jersey, polyester, and cotton fabrics, with ongoing research aimed at expanding its technology to other natural and synthetic materials. The foundation of Colorifix stemmed from a collaboration between its founders, who previously developed a biosensor for detecting arsenic in drinking water, highlighting their commitment to innovation and sustainability in the textile industry.

52 North Health is focused on enhancing healthcare for cancer patients, specifically those undergoing chemotherapy, by providing a portable and easy-to-use medical device. This device employs artificial intelligence to assess the risk of neutropenic sepsis, a serious and potentially fatal side effect of chemotherapy. Through a finger prick blood test and a corresponding digital platform, the device measures a patient's neutrophil count and C-reactive protein (CRP) levels at home. This functionality allows for timely identification of patients at risk of sepsis, thereby improving their safety and quality of life. By facilitating rapid management of their condition, 52 North Health offers a reliable and cost-effective solution for cancer patients.

Tenyks is a software tool that explains why a neural network made a specific decision or provided an output, down to a single node level.

BKwai is a developer of a software platform focused on enhancing infrastructure asset management throughout its lifecycle. By utilizing data from on-site sensors and satellite imagery, combined with artificial intelligence and structural engineering expertise, BKwai provides engineers with critical insights to monitor the structural health of infrastructure. The company's mission is to harness the power of data to improve construction and asset management, enabling infrastructure to operate more intelligently, efficiently, and safely. BKwai aims to help engineers maximize the potential of site data, ultimately contributing to a more resilient built environment.

Semarion is a spin-out company from the Cavendish Laboratory at the University of Cambridge, operating at the edge of the physical and life sciences. Semarion combines microchip industry materials and techniques engineering and cell biology to tackle unmet drug screening needs.

Barocal is a Zero-carbon refrigeration.

Zetta Genomics is a Cambridge-based company established in 2018 that focuses on managing large-scale genomic data to advance precision medicine. The company operates a user-centric platform that facilitates connections between individuals and researchers, allowing users to opt in or out of studies related to various health conditions, including common disorders like eczema and diabetes, as well as rare diseases such as muscular dystrophy. By employing distributed database technology and robust security measures, Zetta Genomics ensures the privacy of genomic data while enabling scientists to access dynamic health and genetic datasets for personalized medicine research. The platform emphasizes transparency and control for users throughout the data-sharing process.

Carbon Re specializes in the decarbonization of high-emission industries, focusing on sectors such as cement, steel, metals, bulk chemicals, glass, paper, and ceramics. The company has developed a cloud-based Foundation Platform that integrates advanced continuous improvement techniques with artificial intelligence. This platform aims to enhance operational efficiencies while significantly reducing greenhouse gas emissions in manufacturing processes. By leveraging this technology, Carbon Re enables its clients to achieve reductions in emissions of up to 20%, resulting in substantial savings on electricity, fuel, and carbon costs for each plant annually.

Echion Technologies Ltd. is a company based in Cambridge, United Kingdom, that specializes in the development and manufacture of lithium-ion batteries for mobile devices and the automotive industry. Founded in 2017 as a spinout from the University of Cambridge Engineering Department, Echion leverages proprietary battery active materials to create next-generation batteries. The company's focus is on producing anode materials designed to facilitate fast charging for electric vehicles, promoting sustainable electrification across various applications. By optimizing power anode materials, Echion aims to provide cost-effective solutions for battery production, contributing to a more sustainable future in energy storage and usage.

Porotech is a spin-out from the University of Cambridge. It mainly focuses on the development of wide-bandgap compound GaN semiconductors by applying material technologies and solutions to unleash the full potential of GaN to revolutionize the electronics industry. The company was co-founded by Dr. Tongtong Zhu, Dr. Yingjun Liu, and Prof. Rachel Oliver.

Porotech is a spin-out from the University of Cambridge. It mainly focuses on the development of wide-bandgap compound GaN semiconductors by applying material technologies and solutions to unleash the full potential of GaN to revolutionize the electronics industry. The company was co-founded by Dr. Tongtong Zhu, Dr. Yingjun Liu, and Prof. Rachel Oliver.

Kvasir Analytics is an AI knowledge management software company.

Abselion specializes in the development of biosensors aimed at enhancing the analysis of biological substances, such as proteins and small molecules, for pharmaceutical research and manufacturing. The company's innovative diagnostic analyzers and kits facilitate the study of biomolecular interactions, including protein interaction analysis. By providing a rapid and cost-effective means of detecting biological materials, Abselion enables researchers to achieve sensitive and near real-time medical diagnoses, thereby simplifying the analytical processes essential for advancing pharmaceutical research.

Developer of a cloud-based platform designed to improve cancer treatment through the prediction of patients' responses. The company's platform identifies optimal treatment for an individual, reduces treatment resistance, and offers patient-specific cancer progression and evidence-based personalized treatment plans, enabling users to proactively adapt treatment before it becomes ineffective.

CB2Tech is a developer of high-power battery technology used to serve automotive applications. It researches and develops battery technology that could have a higher power, recharge at a faster speed and store large amounts of energy that helps the automotive industry with solutions for high-power applications.

Cambridge GaN Devices is a developer of semiconductors focused on designing, creating, and commercializing gallium nitride-based power devices. The company's transistors offer higher speed, significantly lower power loss, and reduced size compared to traditional silicon alternatives. These advancements result in lower energy consumption and enhanced power storage and conversion capabilities. As a result, Cambridge GaN Devices provides industries with compact semiconductors tailored for critical applications across various market segments.

NiftPad is a platform that allows brands to create and sell unique digital assets without requiring any coding skills. Founded in October 2021 as a spin-off from the University of Cambridge, NiftPad offers a white-label shop solution that enables enterprises to launch non-fungible token projects with ease. The platform provides businesses with the tools to build fully customizable online stores, facilitating the issuance and sale of digital assets. This innovative approach helps brands diversify their revenue streams and engage with their communities in novel ways, making digital asset management accessible to a wider range of enterprises. NiftPad is backed by notable investors, including Animoca Brands and Brinc.

Sano Genetics is a user-centric genetic data marketplace that connects individuals directly to the research world. It act as ethical brokers to facilitate a direct connection between you and research institutions. The company was founded in 2017 and is headquartered in Cambridge.

Sano Genetics is a user-centric genetic data marketplace that connects individuals directly to the research world. It act as ethical brokers to facilitate a direct connection between you and research institutions. The company was founded in 2017 and is headquartered in Cambridge.

Riverlane is the most advanced quantum computing software developer

Nu Quantum Ltd is a Cambridge-based company that specializes in the development of quantum photonics hardware, including photon sources and detectors, as well as quantum cryptography systems. Founded in 2018, the company focuses on creating nano-engineered materials that facilitate light generation at the quantum level and enable ultra-sensitive light detection. It also develops fundamental algorithms and protocols for generating secure cryptographic keys and offers quantum encryption links for secure communications. By integrating novel materials and semiconductor technology, Nu Quantum aims to provide end-to-end quantum cryptography solutions that secure communications over urban and satellite free-space optical links, thereby supporting the future of information processing and quantum networking infrastructure.

Sorex Sensors Limited specializes in the design and manufacturing of film bulk acoustic resonator (FBAR) technology-based micro-electro-mechanical system (MEMS) mass sensors for both industrial and consumer applications. The sensors are constructed on silicon wafers and utilize a thin film of piezoelectric material, enabling them to measure mass by detecting changes in resonant frequency when mass is applied to their surface. These sensors are characterized by their dual-mode capability, allowing simultaneous measurement of mass and temperature, with mass sensitivity reaching the femtogram range and temperature resolution down to 0.2 °C. Their compact size and low power consumption make them suitable for various applications, including thin film metrology, particulate monitoring, and gas detection. Sorex Sensors was incorporated in 2017 and is headquartered in the United Kingdom.

Bond180 Limited is a fintech company based in London that focuses on providing technology solutions within the primary debt capital markets. Established in 2019, the company has developed a digital platform that includes a demand management system (DMS) designed to enhance the market-facing activities of institutional investors through improved data and analytics. Additionally, Bond180 offers 180Match, a reverse enquiry engine that facilitates streamlined communication between buyers and sellers in the debt market. The firm also operates an issue administration network, which provides digital asset issuance and administration services to the sell-side. By offering these innovative tools, Bond180 aims to help institutional investors efficiently identify value and source assets for their portfolios.

Colorifix Limited, founded in 2016 and based in Norwich, United Kingdom, specializes in innovative textile dyeing services using biological methods. The company harnesses color-producing organisms, including microbes, plants, animals, and insects, to create a diverse range of colors. By converting agricultural by-products like sugar molasses into environmentally friendly colorants, Colorifix offers a sustainable alternative to traditional dyeing practices. It is recognized as the first company to implement biological dyeing commercially for polyamide-based jersey, polyester, and cotton fabrics, with ongoing research aimed at expanding its technology to other natural and synthetic materials. The foundation of Colorifix stemmed from a collaboration between its founders, who previously developed a biosensor for detecting arsenic in drinking water, highlighting their commitment to innovation and sustainability in the textile industry.

PharmEnable Limited is a drug discovery company based in Cambridge, United Kingdom, that was incorporated in 2016. The company specializes in using medicinal chemistry and artificial intelligence to design small molecule drugs. PharmEnable has developed a rapid and cost-effective method for identifying improved chemical starting points, which aims to enhance the discovery of essential new medicines.

Qkine Ltd, founded in 2016 and based in Cambridge, United Kingdom, specializes in the manufacturing of high-purity, animal-derived component-free (ADCF) growth factors and cytokines. The company emerged from Cambridge University and focuses on providing proteins for stem cell growth, differentiation, and regenerative medicine applications. Utilizing advanced protein engineering and optimized production platforms, Qkine addresses supply chain challenges in stem cell science by delivering novel, animal-free proteins. Their products support life science research, particularly in stem cell and organoid culture, enabling scientists to advance their work with high-quality, bioactive proteins.

Flusso Ltd, established in 2016 and located in Cambridge, United Kingdom, specializes in the development of advanced flow sensors. Currently operating in stealth mode, the company is focused on creating the world's smallest flow sensor, utilizing fabless semiconductor technology to blend hardware, software, and mechanical components. Flusso's innovative sensors are designed to be significantly smaller and more cost-effective, while also enhancing functionality without sacrificing performance. This approach allows the flow sensing industry to benefit from lower power consumption, ultra-fast response times, on-chip multisensory integration, embedded intelligence, and the capability for high-volume production at reduced unit costs.

Xampla Ltd develops and produces a pea plant protein-based plastic material to replace microplastics for commercial use. The company’s products include microcapsules for application in homecare and personal care products; and films, coatings, and single use plastics for application in single and multi-layer films, coatings, and packaging products. Xampla Ltd was incorporated in 2018 and is based in Cambridge, United Kingdom.

Porotech is a spin-out from the University of Cambridge. It mainly focuses on the development of wide-bandgap compound GaN semiconductors by applying material technologies and solutions to unleash the full potential of GaN to revolutionize the electronics industry. The company was co-founded by Dr. Tongtong Zhu, Dr. Yingjun Liu, and Prof. Rachel Oliver.

Kalium Health Ltd is a company based in Cambridge, United Kingdom, that specializes in the design, development, and manufacturing of a finger-prick blood test for measuring blood potassium concentration. This innovative testing method allows patients to seek treatment proactively, avoiding the inconveniences, costs, and delays associated with traditional testing methods. Established in 2018 and formerly known as Kalium Diagnostics Ltd, the company focuses on personalized electrolyte diagnostics aimed at enhancing kidney care. By utilizing advanced electrolyte sensing technology, Kalium Health provides accurate and real-time testing that delivers clinically actionable health insights related to cardiorenal diseases, enabling patients to obtain precise blood electrolyte data for better health management.

AudioTelligence Ltd is a company based in Cambridge, United Kingdom, founded in 2017, that specializes in real-time audio processing technology aimed at improving automatic speech recognition (ASR) systems. The company utilizes an innovative approach known as blind audio signal separation, which allows it to effectively distinguish target voices from background noise without relying on high-quality microphones. This technology enhances the clarity and intelligibility of audio, making it easier for humans and voice-activated devices to engage in conversations despite challenging acoustic environments. AudioTelligence's solutions outperform traditional methods such as beamforming and spectral masking, positioning the company as a leader in the field of audio enhancement.

Tenyks is a software tool that explains why a neural network made a specific decision or provided an output, down to a single node level.

Cambridge Energy Partners is a manufacturer of mobile solar trackers for the global commercial and industrial sector. Their trackers look and perform like traditional solar when installed, but arrive at site in prefabricated units, ready for fast deployment and connection (4x faster than traditional installations). Their product is a truly scalable mobile solar tracker, and offers users 'big solar'​ quality, while also reducing stranded asset risk - enabling the owner to deploy the asset multiple times over its 25-year useful life.

Spirea Ltd. operates as a healthcare technology company that has developed a smart polymer platform for the controlled delivery of drug combinations to maximise the clinical impact of medicines.

Porotech is a spin-out from the University of Cambridge. It mainly focuses on the development of wide-bandgap compound GaN semiconductors by applying material technologies and solutions to unleash the full potential of GaN to revolutionize the electronics industry. The company was co-founded by Dr. Tongtong Zhu, Dr. Yingjun Liu, and Prof. Rachel Oliver.

Nu Quantum Ltd is a Cambridge-based company that specializes in the development of quantum photonics hardware, including photon sources and detectors, as well as quantum cryptography systems. Founded in 2018, the company focuses on creating nano-engineered materials that facilitate light generation at the quantum level and enable ultra-sensitive light detection. It also develops fundamental algorithms and protocols for generating secure cryptographic keys and offers quantum encryption links for secure communications. By integrating novel materials and semiconductor technology, Nu Quantum aims to provide end-to-end quantum cryptography solutions that secure communications over urban and satellite free-space optical links, thereby supporting the future of information processing and quantum networking infrastructure.

Bond180 Limited is a fintech company based in London that focuses on providing technology solutions within the primary debt capital markets. Established in 2019, the company has developed a digital platform that includes a demand management system (DMS) designed to enhance the market-facing activities of institutional investors through improved data and analytics. Additionally, Bond180 offers 180Match, a reverse enquiry engine that facilitates streamlined communication between buyers and sellers in the debt market. The firm also operates an issue administration network, which provides digital asset issuance and administration services to the sell-side. By offering these innovative tools, Bond180 aims to help institutional investors efficiently identify value and source assets for their portfolios.

PredictImmune Ltd is a company based in Cambridge, United Kingdom, focused on developing prognostic tests for immune-mediated inflammatory diseases. Its primary product, PredictSURE IBD, is designed to guide treatment options for patients with Inflammatory Bowel Disease, including Crohn's disease and ulcerative colitis. This innovative test utilizes a small blood sample to accurately identify patients at the time of diagnosis who are at risk for severe, relapsing disease. By providing essential information regarding long-term clinical prognosis, the test supports healthcare professionals in determining personalized treatment plans, particularly the timely use of biologics therapy. PredictImmune's approach is recognized as beneficial by physicians, patients, and payors, as it enhances the management of Inflammatory Bowel Disease and improves patient outcomes.

Paragraf Ltd. is a graphene technology development company based in Somersham, United Kingdom, established in 2015. The company specializes in the production of two-dimensional materials, particularly graphene, and focuses on developing graphene-based electronic devices, green energy generation devices such as solar photovoltaic cells, and various sensors. By leveraging innovative methods, Paragraf aims to unlock the full potential of graphene and advance its applications across multiple technology sectors. The company's commitment to driving the adoption of this versatile material positions it as a key player in the field of advanced materials and their transformative capabilities.

Riverlane is the most advanced quantum computing software developer

Qkine Ltd, founded in 2016 and based in Cambridge, United Kingdom, specializes in the manufacturing of high-purity, animal-derived component-free (ADCF) growth factors and cytokines. The company emerged from Cambridge University and focuses on providing proteins for stem cell growth, differentiation, and regenerative medicine applications. Utilizing advanced protein engineering and optimized production platforms, Qkine addresses supply chain challenges in stem cell science by delivering novel, animal-free proteins. Their products support life science research, particularly in stem cell and organoid culture, enabling scientists to advance their work with high-quality, bioactive proteins.

PolyProx Therapeutics is developer of a novel class of drug intended to provide new therapies for cancer treatment. The company's drug will use novel engineered protein that is able to selectively target tumour cells and trigger natural degradation machinery within the cell, enabling cancer patients to benefit from the treatment that targets and remove disease-causing proteins.

Sano Genetics is a user-centric genetic data marketplace that connects individuals directly to the research world. It act as ethical brokers to facilitate a direct connection between you and research institutions. The company was founded in 2017 and is headquartered in Cambridge.

Morphogen-IX Limited is a biotechnology company based in Cambridge, United Kingdom, focused on developing novel treatments for pulmonary arterial hypertension (PAH), a serious condition affecting lung blood vessels that can lead to heart failure. Founded in 2015 by Index Ventures, the company is exploring the therapeutic potential of bone morphogenetic proteins (BMPs), particularly BMP9 and BMP10, which have shown promise in enhancing BMPR-II receptor signaling in endothelial cells. This signaling is crucial for reversing the effects of PAH, as compromised BMPR-II signaling is central to the disease's pathology. Current PAH treatments primarily address symptoms, and effective long-term solutions are limited, often requiring risky lung transplants. Morphogen-IX employs a semi-virtual business model, leveraging a network of experienced professionals in drug discovery while maintaining operational efficiency through outsourcing. The company's founders are recognized experts in both PAH and BMP research, positioning Morphogen-IX to potentially transform the treatment landscape for this life-limiting disease.

Colorifix Limited, founded in 2016 and based in Norwich, United Kingdom, specializes in innovative textile dyeing services using biological methods. The company harnesses color-producing organisms, including microbes, plants, animals, and insects, to create a diverse range of colors. By converting agricultural by-products like sugar molasses into environmentally friendly colorants, Colorifix offers a sustainable alternative to traditional dyeing practices. It is recognized as the first company to implement biological dyeing commercially for polyamide-based jersey, polyester, and cotton fabrics, with ongoing research aimed at expanding its technology to other natural and synthetic materials. The foundation of Colorifix stemmed from a collaboration between its founders, who previously developed a biosensor for detecting arsenic in drinking water, highlighting their commitment to innovation and sustainability in the textile industry.

Healthera Ltd. is a healthcare technology company based in Cambridge, United Kingdom, that develops an application designed to enhance medication management for patients. The Healthera application integrates with local pharmacies to provide a personalized notification system that helps users remember to take their medications and facilitates communication with pharmacists. The platform supports smart prescription labeling, automatic scheduling, and access to professional medical advice. Additionally, Healthera offers Serket, a tool focused on ensuring medication adherence. By partnering with over 1,000 pharmacies and clinical commissioning groups across the UK, Healthera reaches more than 20 million patients. The company aims to digitize and automate primary care processes, improving the efficiency of prescribing and enhancing the overall patient experience. Recognized for its innovative approach, Healthera's technology is accredited by NHS Digital, positioning it as one of the fastest-growing digital health companies in Europe.

Silicon Microgravity Limited, founded in 2014 and based in Cambridge, United Kingdom, specializes in developing advanced sensor devices for the oil and gas industry. Originating as a spin-out from Cambridge University, the company’s technology enables high-sensitivity gravity data recording and ultra-low frequency seismic data analysis, significantly enhancing the management of oil and gas reservoirs. Developed in collaboration with BP and supported by Innovate UK, its microelectromechanical system sensors allow for precise measurement of densities deep within reservoirs from boreholes. Additionally, the technology has applications in navigation, guidance, and stabilization for various commercial, industrial, and military uses. With its innovative approach, Silicon Microgravity aims to improve reservoir surveillance and operational efficiencies while addressing social, safety, and environmental objectives.

Sorex Sensors Limited specializes in the design and manufacturing of film bulk acoustic resonator (FBAR) technology-based micro-electro-mechanical system (MEMS) mass sensors for both industrial and consumer applications. The sensors are constructed on silicon wafers and utilize a thin film of piezoelectric material, enabling them to measure mass by detecting changes in resonant frequency when mass is applied to their surface. These sensors are characterized by their dual-mode capability, allowing simultaneous measurement of mass and temperature, with mass sensitivity reaching the femtogram range and temperature resolution down to 0.2 °C. Their compact size and low power consumption make them suitable for various applications, including thin film metrology, particulate monitoring, and gas detection. Sorex Sensors was incorporated in 2017 and is headquartered in the United Kingdom.

Cambridge Touch Technologies Ltd. is a company based in Cambridge, United Kingdom, founded in 2011. It specializes in the development of piezoelectric-based 3D touch technology, particularly its next-generation UltraTouch technology, which is designed for smart devices, including smartphones, tablets, and automotive applications. The UltraTouch system integrates a proprietary AI engine that utilizes advanced signal processing algorithms with a specialized Piezoelectric Force Film. This innovative combination allows for a versatile touch and force sensor architecture that is not only cost-effective but also adaptable to various device sizes and shapes, including curved and foldable designs.

PhoreMost Limited, a drug discovery company, engages in identifying new druggable targets for cancer and other unmet diseases. It develops Site-Seeker, a platform that systematically unmasks druggable sites in the human genome and links them to useful therapeutic functions in a live-cell context. The company was incorporated in 2014 and is based in Cambridge, United Kingdom.

Qkine Ltd, founded in 2016 and based in Cambridge, United Kingdom, specializes in the manufacturing of high-purity, animal-derived component-free (ADCF) growth factors and cytokines. The company emerged from Cambridge University and focuses on providing proteins for stem cell growth, differentiation, and regenerative medicine applications. Utilizing advanced protein engineering and optimized production platforms, Qkine addresses supply chain challenges in stem cell science by delivering novel, animal-free proteins. Their products support life science research, particularly in stem cell and organoid culture, enabling scientists to advance their work with high-quality, bioactive proteins.

Paragraf Ltd. is a graphene technology development company based in Somersham, United Kingdom, established in 2015. The company specializes in the production of two-dimensional materials, particularly graphene, and focuses on developing graphene-based electronic devices, green energy generation devices such as solar photovoltaic cells, and various sensors. By leveraging innovative methods, Paragraf aims to unlock the full potential of graphene and advance its applications across multiple technology sectors. The company's commitment to driving the adoption of this versatile material positions it as a key player in the field of advanced materials and their transformative capabilities.

Cytora transforms underwriting for commercial insurance. The Cytora Risk Engine uses artificial intelligence to learn the patterns of risks over time, enabling insurers to underwrite more efficiently and deliver fairer prices to customers. The company's goal is to raise the insurance industry to a new standard where insurance is fast and built on a foundation of tractable data. The company's products allow insurers to enhance underwriting profitability. Cytora was founded on 2014 and is headquartered in London.

PredictImmune Ltd is a company based in Cambridge, United Kingdom, focused on developing prognostic tests for immune-mediated inflammatory diseases. Its primary product, PredictSURE IBD, is designed to guide treatment options for patients with Inflammatory Bowel Disease, including Crohn's disease and ulcerative colitis. This innovative test utilizes a small blood sample to accurately identify patients at the time of diagnosis who are at risk for severe, relapsing disease. By providing essential information regarding long-term clinical prognosis, the test supports healthcare professionals in determining personalized treatment plans, particularly the timely use of biologics therapy. PredictImmune's approach is recognized as beneficial by physicians, patients, and payors, as it enhances the management of Inflammatory Bowel Disease and improves patient outcomes.

Z Factor Limited is a drug discovery company based in Cambridge, United Kingdom, established in 2014. The company focuses on identifying and developing therapeutic agents to address alpha-1-antitrypsin deficiency, a genetic disorder that leads to significant health complications. Z Factor's research aims to design novel therapeutic solutions that correct the misfolding of the Z variant of alpha-1-antitrypsin, addressing a critical medical need. Current treatment options are limited, primarily relying on lung or liver transplantation and augmentation therapy. Through its innovative approach, Z Factor seeks to create effective therapies that could improve the quality of life for those affected by this condition.

Focal Point Positioning Ltd. specializes in advanced positioning technologies, focusing on smartphone-based sensor fusion, machine learning, and signal processing to enhance satellite positioning capabilities in previously inaccessible areas. Founded in 2015 and based in Cambridge, United Kingdom, the company offers consultancy services in positioning, navigation, and timing, addressing challenges related to GNSS, GPS-denied environments, and emerging quantum sensing technologies. Focal Point has developed two key products: S-GNSS, which significantly enhances the sensitivity and accuracy of GPS receivers for indoor and remote tracking, and D-Tail, which utilizes existing smartphone and wearable device sensors for precise three-dimensional user tracking. The company serves a diverse range of industries, including defense, security, aerospace, autonomy, telecom, retail, logistics, and emergency services. Dr. Ramsey Faragher, the founder, is a recognized expert in GNSS-denied positioning, with a distinguished background in developing innovative technologies for military and space applications.

Cytora transforms underwriting for commercial insurance. The Cytora Risk Engine uses artificial intelligence to learn the patterns of risks over time, enabling insurers to underwrite more efficiently and deliver fairer prices to customers. The company's goal is to raise the insurance industry to a new standard where insurance is fast and built on a foundation of tractable data. The company's products allow insurers to enhance underwriting profitability. Cytora was founded on 2014 and is headquartered in London.

Polypharmakos Limited discovers and develops antimicrobials from plants, fungi, and other natural product sources to address the antimicrobial resistance crisis. The company was founded in 2016 and is based in Witney, United Kingdom.

Cambridge Touch Technologies Ltd. is a company based in Cambridge, United Kingdom, founded in 2011. It specializes in the development of piezoelectric-based 3D touch technology, particularly its next-generation UltraTouch technology, which is designed for smart devices, including smartphones, tablets, and automotive applications. The UltraTouch system integrates a proprietary AI engine that utilizes advanced signal processing algorithms with a specialized Piezoelectric Force Film. This innovative combination allows for a versatile touch and force sensor architecture that is not only cost-effective but also adaptable to various device sizes and shapes, including curved and foldable designs.

Carrick Therapeutics, Ltd., founded in 2015 and based in Dublin, Ireland, focuses on developing innovative cancer therapeutics aimed at transforming cancer treatment. The company targets specific molecular pathways associated with aggressive and resistant cancer forms, allowing for early detection of predictive biomarkers. This approach facilitates timely treatment initiation for patients, enhancing the potential for improved outcomes in cancer care.

PervasID Limited, founded in 2011 and based in Cambridge, United Kingdom, specializes in the development of wide area passive RFID systems. The company emerged from research conducted at the University of Cambridge and focuses on providing location capabilities based on the EPC Class1 Gen2 standard. PervasID's technology employs fixed ultra-high frequency RFID to accurately detect passive tags over long distances, facilitating enhanced visibility into goods, assets, and people. Its innovative systems are designed to serve various industries, including retail, healthcare, supply chain and logistics, and aviation. The technology has been successfully deployed in multiple field trials, demonstrating its reliability and effectiveness in streamlining processes across diverse markets.

Fluidic Analytics Limited designs, develops, and manufactures equipment for the characterization of proteins in laboratory, medical, and consumer applications. The company provides Fluidity One, a product that enables in-solution sizing and quantification of native protein. The company also offers Fluidity One-W, a product that enables high sensitivity in-solution analysis of protein size and protein interaction kinetics. Its products are used for applications, including protein quality, interactions, aggregation, and sizing. The company serves scientists, clinics, and healthcare providers. Fluidic Analytics Limited was founded in 2013 and is based in Cambridge, United Kingdom.

Healthera Ltd. is a healthcare technology company based in Cambridge, United Kingdom, that develops an application designed to enhance medication management for patients. The Healthera application integrates with local pharmacies to provide a personalized notification system that helps users remember to take their medications and facilitates communication with pharmacists. The platform supports smart prescription labeling, automatic scheduling, and access to professional medical advice. Additionally, Healthera offers Serket, a tool focused on ensuring medication adherence. By partnering with over 1,000 pharmacies and clinical commissioning groups across the UK, Healthera reaches more than 20 million patients. The company aims to digitize and automate primary care processes, improving the efficiency of prescribing and enhancing the overall patient experience. Recognized for its innovative approach, Healthera's technology is accredited by NHS Digital, positioning it as one of the fastest-growing digital health companies in Europe.

8power Limited manufacture autonomous sensor systems for automotive and transportation, civil engineering, industrial equipment, and utility infrastructure sectors.

PsyOmics develops proteomic diagnostics to improve early diagnosis and treatment outcomes for those with neuropsychiatric disorders.

DefiniGEN Limited specializes in providing human cell products for the life sciences and drug discovery sectors. The company's offerings include various types of human hepatocytes and pancreatic cells, which are essential for research on conditions such as diabetes, hepatitis, hypercholesterolemia, and glycogen storage diseases. DefiniGEN has developed a unique platform for producing induced pluripotent stem cells (iPSCs), enabling it to create highly predictive in vitro cell products that enhance drug discovery processes for pharmaceutical companies. In addition to its cell products, the company offers services such as custom cell production, compound profiling, gene-editing, and iPS differentiation. Established in 2011 and based in Cambridge, UK, DefiniGEN draws on the expertise and intellectual property developed at the University of Cambridge, particularly in regenerative medicine and metabolic disease modeling.

ROADMap Systems Limited is a technology company based in Cambridge, United Kingdom, specializing in wavelength selective switch (WSS) technology for fiber optic communication networks. Established in 2013, the company focuses on developing optical and wavelength selective switches that facilitate the creation of reconfigurable optical add/drop multiplexers (ROADMs). These switches address the growing demands of network operators facing challenges related to increasing data capacity, managing operational and capital expenses, and adapting to rapidly changing service requirements. By leveraging patented technology from the Cambridge Centre for Advanced Photonics and Electronics, ROADMap offers solutions that enable flexible optical switching capable of supporting next-generation 400 Gbps data rates, thus providing clients with cost-effective and future-proof options for their telecommunications and data communication needs.

Cambridge Epigenetix Limited is a bioscience company based in Babraham, United Kingdom, focused on advancing clinical epigenetics. Founded in 2012, the company specializes in developing innovative tools for epigenetic analysis, particularly through its TrueMethyl technology, which allows for precise sequencing of hydroxymethylcytosine (5hmC) and methylcytosine (5mC). Its product offerings include TrueMethyl 6 and TrueMethyl 24 kits, designed for quantitative measurement and single-base resolution analysis of DNA methylation and hydroxymethylation. Cambridge Epigenetix aims to transform medical diagnostics by simplifying tests for colorectal cancer and other tumors to a single blood draw, leveraging the significant biomarker potential of 5hmC. The company emerged from the University of Cambridge, backed by notable investors including GV, Sequoia, and Syncona. Through its work, Cambridge Epigenetix seeks to enhance diagnostic and prognostic capabilities in medicine, aligning with its mission to improve human health.

Silicon Microgravity Limited, founded in 2014 and based in Cambridge, United Kingdom, specializes in developing advanced sensor devices for the oil and gas industry. Originating as a spin-out from Cambridge University, the company’s technology enables high-sensitivity gravity data recording and ultra-low frequency seismic data analysis, significantly enhancing the management of oil and gas reservoirs. Developed in collaboration with BP and supported by Innovate UK, its microelectromechanical system sensors allow for precise measurement of densities deep within reservoirs from boreholes. Additionally, the technology has applications in navigation, guidance, and stabilization for various commercial, industrial, and military uses. With its innovative approach, Silicon Microgravity aims to improve reservoir surveillance and operational efficiencies while addressing social, safety, and environmental objectives.

Morphogen-IX Limited is a biotechnology company based in Cambridge, United Kingdom, focused on developing novel treatments for pulmonary arterial hypertension (PAH), a serious condition affecting lung blood vessels that can lead to heart failure. Founded in 2015 by Index Ventures, the company is exploring the therapeutic potential of bone morphogenetic proteins (BMPs), particularly BMP9 and BMP10, which have shown promise in enhancing BMPR-II receptor signaling in endothelial cells. This signaling is crucial for reversing the effects of PAH, as compromised BMPR-II signaling is central to the disease's pathology. Current PAH treatments primarily address symptoms, and effective long-term solutions are limited, often requiring risky lung transplants. Morphogen-IX employs a semi-virtual business model, leveraging a network of experienced professionals in drug discovery while maintaining operational efficiency through outsourcing. The company's founders are recognized experts in both PAH and BMP research, positioning Morphogen-IX to potentially transform the treatment landscape for this life-limiting disease.

Cytora transforms underwriting for commercial insurance. The Cytora Risk Engine uses artificial intelligence to learn the patterns of risks over time, enabling insurers to underwrite more efficiently and deliver fairer prices to customers. The company's goal is to raise the insurance industry to a new standard where insurance is fast and built on a foundation of tractable data. The company's products allow insurers to enhance underwriting profitability. Cytora was founded on 2014 and is headquartered in London.

Quethera is a gene therapy company dedicated to improving the future treatment of common blinding eye diseases. Our initial focus is on developing therapies to reduce progressive visual loss in glaucoma and other conditions affecting the optic nerve. Quethera is working alongside world leaders in the glaucoma field to design clinical trials capable of examining the efficacy and safety of novel therapies in patients who lose parts of their visual field at an accelerated rate (fast-progressors). The company has expertise in gene therapeutic design and development sufficient to progress its pipeline through preclinical testing and into clinical development.

Focal Point Positioning Ltd. specializes in advanced positioning technologies, focusing on smartphone-based sensor fusion, machine learning, and signal processing to enhance satellite positioning capabilities in previously inaccessible areas. Founded in 2015 and based in Cambridge, United Kingdom, the company offers consultancy services in positioning, navigation, and timing, addressing challenges related to GNSS, GPS-denied environments, and emerging quantum sensing technologies. Focal Point has developed two key products: S-GNSS, which significantly enhances the sensitivity and accuracy of GPS receivers for indoor and remote tracking, and D-Tail, which utilizes existing smartphone and wearable device sensors for precise three-dimensional user tracking. The company serves a diverse range of industries, including defense, security, aerospace, autonomy, telecom, retail, logistics, and emergency services. Dr. Ramsey Faragher, the founder, is a recognized expert in GNSS-denied positioning, with a distinguished background in developing innovative technologies for military and space applications.

Reduse Limited, founded in 2015 and based in Cambridge, United Kingdom, specializes in print removal services using advanced laser technology. The company's innovative process, known as "unprinting," effectively eliminates ink from printed papers, allowing for the reuse of sheets that would otherwise be discarded. This technology helps organizations reduce waste and minimize their carbon footprint by enabling the recycling of office paper. By addressing common paper waste issues, Reduse contributes to more sustainable business practices in office environments.

Fluidic Analytics Limited designs, develops, and manufactures equipment for the characterization of proteins in laboratory, medical, and consumer applications. The company provides Fluidity One, a product that enables in-solution sizing and quantification of native protein. The company also offers Fluidity One-W, a product that enables high sensitivity in-solution analysis of protein size and protein interaction kinetics. Its products are used for applications, including protein quality, interactions, aggregation, and sizing. The company serves scientists, clinics, and healthcare providers. Fluidic Analytics Limited was founded in 2013 and is based in Cambridge, United Kingdom.

Cambridge Epigenetix Limited is a bioscience company based in Babraham, United Kingdom, focused on advancing clinical epigenetics. Founded in 2012, the company specializes in developing innovative tools for epigenetic analysis, particularly through its TrueMethyl technology, which allows for precise sequencing of hydroxymethylcytosine (5hmC) and methylcytosine (5mC). Its product offerings include TrueMethyl 6 and TrueMethyl 24 kits, designed for quantitative measurement and single-base resolution analysis of DNA methylation and hydroxymethylation. Cambridge Epigenetix aims to transform medical diagnostics by simplifying tests for colorectal cancer and other tumors to a single blood draw, leveraging the significant biomarker potential of 5hmC. The company emerged from the University of Cambridge, backed by notable investors including GV, Sequoia, and Syncona. Through its work, Cambridge Epigenetix seeks to enhance diagnostic and prognostic capabilities in medicine, aligning with its mission to improve human health.

DefiniGEN Limited specializes in providing human cell products for the life sciences and drug discovery sectors. The company's offerings include various types of human hepatocytes and pancreatic cells, which are essential for research on conditions such as diabetes, hepatitis, hypercholesterolemia, and glycogen storage diseases. DefiniGEN has developed a unique platform for producing induced pluripotent stem cells (iPSCs), enabling it to create highly predictive in vitro cell products that enhance drug discovery processes for pharmaceutical companies. In addition to its cell products, the company offers services such as custom cell production, compound profiling, gene-editing, and iPS differentiation. Established in 2011 and based in Cambridge, UK, DefiniGEN draws on the expertise and intellectual property developed at the University of Cambridge, particularly in regenerative medicine and metabolic disease modeling.

DefiniGEN Limited specializes in providing human cell products for the life sciences and drug discovery sectors. The company's offerings include various types of human hepatocytes and pancreatic cells, which are essential for research on conditions such as diabetes, hepatitis, hypercholesterolemia, and glycogen storage diseases. DefiniGEN has developed a unique platform for producing induced pluripotent stem cells (iPSCs), enabling it to create highly predictive in vitro cell products that enhance drug discovery processes for pharmaceutical companies. In addition to its cell products, the company offers services such as custom cell production, compound profiling, gene-editing, and iPS differentiation. Established in 2011 and based in Cambridge, UK, DefiniGEN draws on the expertise and intellectual property developed at the University of Cambridge, particularly in regenerative medicine and metabolic disease modeling.

Horizon Discovery Group PLC is a UK life science company that uses gene editing and gene modulation platforms to produce cells, applying them in research and clinical applications that advance human health. The Company’s gene editing and gene modulation platform, are able to alter almost any DNA sequence or RNA transcription, has generated a catalogue of over 1,000,000 cell and reagent products that help researchers recapitulate the genetic and protein anomalies found in diseases like cancer. These models have been adopted by c12, 000 organizations to better understand of the predictors and drivers of disease and drug response, and by Horizon in a range of services offered to customers, as well as in the Company’s own research R&D pipeline.

PneumaCare Limited specializes in the development of non-invasive systems for assessing and monitoring lung function, particularly in vulnerable populations such as infants, intensive care patients, and the elderly. The company's primary product, PneumaScan, utilizes structured light plethysmography to capture motion and assess thoraco-abdominal volume without requiring direct contact with patients. This innovative approach allows for natural breathing assessments and spirometric maneuvers, thereby minimizing discomfort and infection risk associated with traditional spirometry. PneumaCare's product line includes various models such as Thora-3Di, Thora-3Di Infant, and Thora3Di Remote, which are designed for diverse clinical applications. Founded in 2008 and based in Ely, United Kingdom, PneumaCare's technology is supported by research from the University of Cambridge and is currently being evaluated in clinical settings, including prominent hospitals in Cambridge and London.

Enval Limited, founded in 2005 and based in Huntingdon, United Kingdom, specializes in recycling equipment and modular plants designed for the recycling of plastic-aluminium laminates using microwave-induced pyrolysis. Originally a spin-out from the Department of Chemical Engineering at the University of Cambridge, the company focuses on offering innovative solutions to address environmental and regulatory challenges across various sectors, including industrial, commercial, and municipal. Enval provides environmental life cycle analysis and technology consultancy, specifically targeting the pyrolytic recycling of complex flexible packaging materials. Its clients include waste handlers, local authorities, fast-moving consumer goods brands, and individual consumers, all benefiting from Enval's expertise in delivering value from waste.

Cambridge CMOS Sensors (CCS) is an industry leader in sensor technology and a leading manufacturer of sensor solutions and components for monitoring air quality, including hazardous gases and Volatile Organic Compounds (VOCs). Founded in 2008 as a spin-off from Cambridge University, we are revolutionising environmental sensing for health and well-being through a new generation of semiconductor-based sensors. Our technology offers a radical step change in performance, with significantly lower power consumption, ultra-fast response time, embedded intelligence and ultra-small form factor.

Horizon Discovery Group PLC is a UK life science company that uses gene editing and gene modulation platforms to produce cells, applying them in research and clinical applications that advance human health. The Company’s gene editing and gene modulation platform, are able to alter almost any DNA sequence or RNA transcription, has generated a catalogue of over 1,000,000 cell and reagent products that help researchers recapitulate the genetic and protein anomalies found in diseases like cancer. These models have been adopted by c12, 000 organizations to better understand of the predictors and drivers of disease and drug response, and by Horizon in a range of services offered to customers, as well as in the Company’s own research R&D pipeline.

OptiSynx is a new technology company based in Cambridge, UK developing the next generation solid state Stratum 1 frequency standards. Time and frequency standards are extensively used throughout telecommunications and IT networks. With OptiSynx technology customers of accurate time and frequency sources are finally able to obtain what they have been wanting for a long time - a clock of sufficient accuracy that has a low initial cost, low cost of ownership, long lifetime, low maintenance, low power consumption and is robust at the right price point.

Sentinel Oncology Limited, a drug discovery company, develops and commercializes therapeutics to treat cancer. The company develops small molecule approaches to target the microenvironment of solid tumors. Its R&D programs pipeline includes Checkpoint Kinase 1, a protein kinase that activates in response to DNA damage and DNA replication stress; and an approach to treat metastatic breast cancer by developing a drug that inhibits S6K1 and offers treatment options for patients. The company was founded in 2005 and is based in Cambridge, United Kingdom.

Developing anti-cancer & anti-microbial photocontrollable peptidic therapies

Psynova Neurotech is exclusively focused on the commercial development and exploitation of novel biomarkers for Neuropsychiatric and other mental illnesses.

Sentinel Oncology Limited, a drug discovery company, develops and commercializes therapeutics to treat cancer. The company develops small molecule approaches to target the microenvironment of solid tumors. Its R&D programs pipeline includes Checkpoint Kinase 1, a protein kinase that activates in response to DNA damage and DNA replication stress; and an approach to treat metastatic breast cancer by developing a drug that inhibits S6K1 and offers treatment options for patients. The company was founded in 2005 and is based in Cambridge, United Kingdom.

Sentinel Oncology Limited, a drug discovery company, develops and commercializes therapeutics to treat cancer. The company develops small molecule approaches to target the microenvironment of solid tumors. Its R&D programs pipeline includes Checkpoint Kinase 1, a protein kinase that activates in response to DNA damage and DNA replication stress; and an approach to treat metastatic breast cancer by developing a drug that inhibits S6K1 and offers treatment options for patients. The company was founded in 2005 and is based in Cambridge, United Kingdom.

BlueGnome Limited specializes in developing genetic diagnostic solutions aimed at screening for chromosomal abnormalities. Based in Fulbourn, United Kingdom, the company gained recognition for its innovative approaches to genetic testing. In 2012, BlueGnome was acquired by Illumina, a leading company in the field of genomics, further enhancing its capabilities and reach in the market for genetic diagnostics.